Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials

References

• Diabetesatlas.org [Internet]. Brussels (Belgium): International Diabetes Federation. IDF Diabetes Atlas; 10th 2021 [cited 2023 Aug 21]. Available from: https://diabetesatlas.org/
   Google Scholar
• King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–1431. doi: 10.2337/diacare.21.9.1414
   PubMed Web of Science ®Google Scholar
• Basu S, Yudkin JS, Kehlenbrink S, et al. Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimulation analysis. Lancet Diabetes Endocrinol. 2019;7(1):25–33. doi: 10.1016/S2213-8587(18)30303-6
   PubMed Web of Science ®Google Scholar
• Gregory GA, Robinson TIG, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741–760. doi: 10.1016/S2213-8587(22)00218-2
   PubMed Web of Science ®Google Scholar
• Yang L-J, Wu T-W, Tang C-H, et al. Efficacy and immunogenicity of insulin biosimilar compared to their reference products: a systematic review and meta-analysis. BMC Endocr Disord. 2022;22(1):35. doi: 10.1186/s12902-022-00944-5
   PubMed Web of Science ®Google Scholar
• Wong EY, Kroon L. Ultra-rapid-acting insulins: how fast is really needed? Clin. Clin Diabetes. 2021;39(4):415–423. doi: 10.2337/cd20-0119
   PubMedGoogle Scholar
• Nicolucci A, Ceriello A, Di Bartolo P, et al. Rapid-acting insulin analogues versus regular human insulin: a meta-analysis of effects on glycemic control in patients with diabetes. Diabetes Ther. 2020;11:573–584. doi: 10.1007/s13300-019-00732-w
   PubMed Web of Science ®Google Scholar
• Guney Z. Insulin and its analogues–what are they for? (pros and cons). Trends Diabetes Metab. 2019;2(2). doi: 10.15761/TDM.1000113
   Google Scholar
• Homko C, Deluzio A, Jimenez C, et al. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care. 2003;26(7):2027–2031. doi: 10.2337/diacare.26.7.2027
   PubMed Web of Science ®Google Scholar
• Novo Nordisk. Fiasp [package insert]. Plainsboro (NJ): Novo Nordisk; 2019 [cited 2024 May 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208751s010s011lbl.pdf
   Google Scholar
• Eli Lilly and Company. Lyumjev. Package insert. (IN)polis: IN, Eli Lilly and Company; 2020 [cited 2024 May 21]. Available from: https://pi.lilly.com/us/lyumjev-uspi.pdf
   Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA–P) 2015 statement. Syst Rev. 2015;4(1):1. doi: 10.1186/2046-4053-4-1
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928
   PubMed Web of Science ®Google Scholar
• Tamborlane WV, Renard E, Wadwa RP, et al. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart. J Diabetes. 2015;7(2):270–278. doi: 10.1111/1753-0407.12162
   PubMed Web of Science ®Google Scholar
• Bartolo PD, Pellicano F, Scaramuzza A, et al. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes. Diabetes Technol Ther. 2008;10(6):495–498. doi: 10.1089/dia.2008.0013
   PubMed Web of Science ®Google Scholar
• Weinzimer SA, Ternand C, Howard C, et al. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care. 2008;31(2):210–215. doi: 10.2337/dc07-1378
   PubMed Web of Science ®Google Scholar
• Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care. 2002;25(3):439–444. doi: 10.2337/diacare.25.3.439
   PubMed Web of Science ®Google Scholar
• Hedman CA, Lindström T, Arnqvist HJ. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care. 2001;24(6):1120–1121. doi: 10.2337/diacare.24.6.1120
   PubMed Web of Science ®Google Scholar
• Liu BL, Yin GP, Li FF, et al. Comparison of efficacy and safety of lispro and aspart evaluated by continuous glucose monitoring system in patients with newly diagnosed type 2 diabetes. Int J Endocrinol. 2018;2018:2087960. doi: 10.1155/2018/2087960
   PubMed Web of Science ®Google Scholar
• Thrasher J, Bhargava A, Rees TM, et al. Insulin lispro with continuous subcutaneous insulin infusion is safe and effective in patients with type 2 diabetes: a randomized crossover trial of insulin lispro versus insulin aspart. Endocr Pract. 2015;21(3):247–257. doi: 10.4158/EP14242.OR
   PubMed Web of Science ®Google Scholar
• Plank J, Wutte A, Brunner G, et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care. 2002;25(11):2053–2057. doi: 10.2337/diacare.25.11.2053
   PubMed Web of Science ®Google Scholar
• Wang T, Malone J, Fu H, et al. Crossover design and its application in late-phase diabetes studies. J Diabetes. 2016;8(5):610–618. doi: 10.1111/1753-0407.12412
   PubMed Web of Science ®Google Scholar
• von Mach MA, Brinkmann C, Hansen T, et al. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp Clin Endocrinol Diabetes. 2002;110(8):416–419. doi: 10.1055/s-2002-36428
   PubMed Web of Science ®Google Scholar
• Lak V, Svensson AM, Miftaraj M, et al. Clinical effects and safety of direct-acting insulin analogs in patients with type 1 diabetes: a nation-wide observational cohort study. Diabetes Ther. 2016;7(3):561–573. doi: 10.1007/s13300-016-0191-x
   PubMed Web of Science ®Google Scholar
• Svensson AM, Miftaraj M, Franzén S, et al. Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study. Clin Diabetes Endocrinol. 2017;3(1):5. doi: 10.1186/s40842-017-0043-2
   PubMedGoogle Scholar
• Racsa PN, Meah Y, Ellis JJ, et al. Comparative effectiveness of rapid-acting insulins in adults with diabetes. J Manag Care Spec Pharm. 2017;23(3):291–298. doi: 10.18553/jmcp.2017.23.3.291
   PubMed Web of Science ®Google Scholar
• Pharmacist.therapeuticresearch.com [Internet]. Delaware: therapeutic research center. How to switch insulin products. 2023 [cited 2023 Oct 9]. Available from: https://pharmacist.therapeuticresearch.com/Content/Segments/PRL/2016/Dec/How-to-Switch-Insulin-Products-10473
   Google Scholar
• Medpagetoday.com [Internet]. MedPage Today. Basen T. What to consider when changing rapid acting insulin products: key differences between the three major types. (NY) (NY); 2019 [updated 2019 Jun 20] [cited 2023 Oct 5]. Available from: https://www.medpagetoday.com/reading-room/endocrine-society/diabetes/80254
   Google Scholar
• Novo-pi.com [Internet]. Plainsboro: Novo Nordisk. Insulin Aspart PI; 2023 [updated 2023 Feb]; cited 2023 Oct 5]. Available from: https://www.novo-pi.com/insulinaspart.pdf
   Google Scholar
• Pi.lilly.com [Internet]. (IN)polis (IN): Eli Lilly and Company. Insulin Lispro USPI; 2023 [updated 2023 Sep] cited 2023 Oct 5]. Available from: https://pi.lilly.com/insulin-lispro-uspi.pdf
   Google Scholar
• Goodrx.com [Internet]. McQueen H, Li D. How much does insulin cost? Here is how 32 brands and generics compare. 2023 [webpage updated 2023 Oct 11; cited 2024 Jan 12]. Available from: https://www.goodrx.com/healthcare-access/research/how-much-does-insulin-cost-compare-brands
   Google Scholar
• Formulary.nhssomerset.nhs.uk [Internet]. Chapter 6.4.2 – Related guidance: A guide to insulin treated diabetes and driving (DVLA). [cited 2024 Jan 12]. Available from: https://formulary.nhssomerset.nhs.uk/?page_id=767
   Google Scholar